BIOSITE DIAGNOSTICS INC
10-Q, EX-27.1, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BIOSITE DIAGNOSTICS INC, 10-Q, 2000-11-14
Next: BROOKE CORP, 10QSB, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
REGISTRANT'S FINANCIAL STATEMENTS AS OF AND FOR THE QUARTER ENDED SEPTEMBER 30,
2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
INCLUDED IN THE COMPANY'S 1999 ANNUAL REPORT ON FORM 10-K.
</LEGEND>
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                           4,866
<SECURITIES>                                    33,914
<RECEIVABLES>                                    6,764
<ALLOWANCES>                                         0
<INVENTORY>                                      7,325
<CURRENT-ASSETS>                                55,685
<PP&E>                                          25,452
<DEPRECIATION>                                  14,640
<TOTAL-ASSETS>                                  78,410
<CURRENT-LIABILITIES>                            7,983
<BONDS>                                          4,198
                                0
                                          0
<COMMON>                                           140
<OTHER-SE>                                      66,089
<TOTAL-LIABILITY-AND-EQUITY>                    78,410
<SALES>                                         13,330
<TOTAL-REVENUES>                                14,971
<CGS>                                            3,936
<TOTAL-COSTS>                                   11,649
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,322
<INCOME-TAX>                                     1,300
<INCOME-CONTINUING>                              2,022
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,022
<EPS-BASIC>                                       0.15<F1>
<EPS-DILUTED>                                     0.13<F1>
<FN>
<F1>EARNINGS PER SHARE IS CALCULATED ON THE BASIS DESCRIBED IN NOTE 2 OF NOTES TO
FINANCIAL STATEMENTS.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission